BPN14770
4 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
4
Ongoing
0
Recruiting
0
Completed
4
Sites
43
Countries
1
Endpoints
27
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 27 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 6 of 27 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
2
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
4 of 4
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03817684Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects | BPN14770 Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 41 | Feb 2020 | - | results |
| NCT03030105Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers | BPN14770, Donepezil Alzheimer’s disease | Age 18-55 | Ph 1 | Completed | 1 | May 2017 | - | |
| NCT02648672BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects | BPN14770 Alzheimer’s disease | Age 18-55 | Ph 1 | Completed | 1 | Feb 2016 | - | |
| NCT02840279A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects | BPN14770 Alzheimer’s disease | Age 25-90 | Ph 1 | Completed | 1 | Nov 2016 | 1 |
Showing 1-4 of 4 trials